285 related articles for article (PubMed ID: 18616687)
21. Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Prisciandaro JJ; DeSantis SM; Bandyopadhyay D
Alcohol Clin Exp Res; 2012 Dec; 36(12):2141-9. PubMed ID: 22551231
[TBL] [Abstract][Full Text] [Related]
22. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
[TBL] [Abstract][Full Text] [Related]
23. What happens when people discontinue taking medications? Lessons from COMBINE.
Stout RL; Braciszewski JM; Subbaraman MS; Kranzler HR; O'Malley SS; Falk D;
Addiction; 2014 Dec; 109(12):2044-52. PubMed ID: 25098969
[TBL] [Abstract][Full Text] [Related]
24. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Berger L; Fisher M; Brondino M; Bohn M; Gwyther R; Longo L; Beier N; Ford A; Greco J; Garbutt JC
Alcohol Clin Exp Res; 2013 Apr; 37(4):668-74. PubMed ID: 23134193
[TBL] [Abstract][Full Text] [Related]
26. Trajectory analyses in alcohol treatment research.
Chen J; Johnson BA; Wang XQ; O'Quigley J; Isaac M; Zhang D; Liu L
Alcohol Clin Exp Res; 2012 Aug; 36(8):1442-8. PubMed ID: 22525000
[TBL] [Abstract][Full Text] [Related]
27. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
[TBL] [Abstract][Full Text] [Related]
28. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
29. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Klemperer EM; Hughes JR; Naud S
Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
[TBL] [Abstract][Full Text] [Related]
30. The effects of drinking goal on treatment outcome for alcoholism.
Bujarski S; O'Malley SS; Lunny K; Ray LA
J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
[TBL] [Abstract][Full Text] [Related]
31. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
32. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Witkiewitz K; Bowen S; Donovan DM
J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
[TBL] [Abstract][Full Text] [Related]
33. An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care.
Ernst DB; Pettinati HM; Weiss RD; Donovan DM; Longabaugh R
Ann Fam Med; 2008; 6(5):435-40. PubMed ID: 18779548
[TBL] [Abstract][Full Text] [Related]
34. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
35. Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Subbaraman MS; Metrik J; Patterson D; Swift R
Addiction; 2017 Apr; 112(4):685-694. PubMed ID: 27865015
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
37. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason BJ
J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
[TBL] [Abstract][Full Text] [Related]
38. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
[TBL] [Abstract][Full Text] [Related]
39. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
40. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Fucito LM; Park A; Gulliver SB; Mattson ME; Gueorguieva RV; O'Malley SS
Biol Psychiatry; 2012 Nov; 72(10):832-8. PubMed ID: 22541040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
